Cat. No. 0867
Chemical Name: 1-(4-Methoxybenzoyl)-2-pyrrolidinon
Biological ActivityNootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Nakamura and Kurasawa (2001) Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur.J.Pharmacol. 420 33. PMID: 11412837.
Isaacson and Nicholl (1991) Aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 88 10936. PMID: 1660156.
Ito et al (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J.Physiol. 424 553. PMID: 1975272.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Aniracetam from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Aniracetam, supplier, Desensitization, inhibitors, inhibits, AMPA, kainate, Glutamate, Receptors, iGluR, Ionotropic, allosteric, modulators, potentiators, Tocris Bioscience, AMPA Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
NMDA receptor modulator; metabolite of Ketamine hydrochloride (Cat. No.3131)2S,6S-Hydroxynorketamine hydrochloride
Potent AMPA agonist; ketamine metabolite2R,6R-Hydroxynorketamine hydrochloride
Potent AMPA agonist; ketamine metabolite(R)-Norketamine hydrochloride
NMDA receptor modulator; metabolite of Ketamine hydrochloride (Cat. No.3131).PEAQX tetrasodium salt
Potent NMDA receptor antagonist; NR2A selective
March 18 - 22, 2017
Little Rock, ARK, USA